Canopy Growth (CGC) Competitors $1.01 -0.02 (-1.94%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.02 +0.01 (+0.99%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CGC vs. PRTA, REPL, ABUS, VECT, KALV, AVBP, TRVI, RCKT, ANAB, and PHARShould you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Prothena (PRTA), Replimune Group (REPL), Arbutus Biopharma (ABUS), VectivBio (VECT), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Rocket Pharmaceuticals (RCKT), AnaptysBio (ANAB), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Canopy Growth vs. Prothena Replimune Group Arbutus Biopharma VectivBio KalVista Pharmaceuticals ArriVent BioPharma Trevi Therapeutics Rocket Pharmaceuticals AnaptysBio Pharming Group Canopy Growth (NASDAQ:CGC) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Do insiders & institutionals have more ownership in CGC or PRTA? 3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 1.3% of Canopy Growth shares are held by insiders. Comparatively, 28.2% of Prothena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, CGC or PRTA? Canopy Growth has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Do analysts recommend CGC or PRTA? Canopy Growth currently has a consensus target price of $2.00, indicating a potential upside of 98.02%. Prothena has a consensus target price of $55.00, indicating a potential upside of 473.51%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Prothena 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community believe in CGC or PRTA? Prothena received 592 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformCanopy GrowthOutperform Votes2019.23%Underperform Votes8480.77% ProthenaOutperform Votes61270.43% Underperform Votes25729.57% Does the media prefer CGC or PRTA? In the previous week, Canopy Growth had 11 more articles in the media than Prothena. MarketBeat recorded 19 mentions for Canopy Growth and 8 mentions for Prothena. Prothena's average media sentiment score of 1.05 beat Canopy Growth's score of 0.11 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 1 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is CGC or PRTA more profitable? Prothena has a net margin of -90.50% compared to Canopy Growth's net margin of -156.98%. Prothena's return on equity of -22.67% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-156.98% -56.52% -24.18% Prothena -90.50%-22.67%-19.68% Which has preferable valuation & earnings, CGC or PRTA? Prothena has lower revenue, but higher earnings than Canopy Growth. Prothena is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy Growth$276.75M0.58-$487.23M-$3.80-0.27Prothena$135.16M3.82-$147.03M-$2.30-4.17 SummaryProthena beats Canopy Growth on 14 of the 18 factors compared between the two stocks. Remove Ads Get Canopy Growth News Delivered to You Automatically Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGC vs. The Competition Export to ExcelMetricCanopy GrowthMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$160.20M$1.17B$5.33B$7.57BDividend YieldN/AN/A5.11%4.33%P/E Ratio-0.279.6921.7317.81Price / Sales0.587.42379.1494.58Price / CashN/A10.4038.1534.64Price / Book0.371.186.464.00Net Income-$487.23M-$56.07M$3.20B$247.23M7 Day Performance21.95%8.39%6.54%7.26%1 Month Performance-8.18%-10.00%-8.55%-6.26%1 Year Performance-85.53%-43.04%10.33%-0.18% Canopy Growth Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGCCanopy Growth2.2202 of 5 stars$1.01-1.9%$2.00+98.0%-85.5%$160.20M$276.75M-0.273,150PRTAProthena3.5303 of 5 stars$10.80-0.5%$55.00+409.1%-56.4%$582.41M$135.16M-4.70130REPLReplimune Group3.5977 of 5 stars$7.53+0.9%$19.43+158.0%+8.3%$576.46MN/A-2.44210ABUSArbutus Biopharma1.768 of 5 stars$3.00-7.2%$5.50+83.5%+6.4%$573.48M$6.17M-6.9690Gap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals4.1958 of 5 stars$11.40+6.4%$24.83+117.9%+2.4%$566.51MN/A-3.13100Gap DownAVBPArriVent BioPharma1.1442 of 5 stars$16.37-0.3%$39.00+138.2%+9.6%$556.88MN/A-6.3740News CoveragePositive NewsGap DownTRVITrevi Therapeutics3.3949 of 5 stars$5.70-5.8%$17.56+208.1%+120.6%$551.09MN/A-12.9520RCKTRocket Pharmaceuticals4.6217 of 5 stars$5.14+0.4%$43.00+736.3%-72.8%$548.61MN/A-1.87240Insider TradeNews CoverageGap UpANABAnaptysBio2.3621 of 5 stars$18.02-2.6%$35.11+94.8%-14.9%$544.92M$91.28M-2.92100Positive NewsPHARPharming Group2.459 of 5 stars$7.97+3.6%$30.00+276.4%-21.2%$542.21M$297.20M-30.65280Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies PRTA Competitors REPL Competitors ABUS Competitors VECT Competitors KALV Competitors AVBP Competitors TRVI Competitors RCKT Competitors ANAB Competitors PHAR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Canopy Growth Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Canopy Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGC Stock Free CGC Stock Alerts